Drugs for Neglected Diseases initiative
http://www.dndi.org
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Drugs for Neglected Diseases initiative
Pipeline Watch: Phase III Top-Line Results With Upadacitinib, Keytruda And Cosentyx
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Kisqali, SI-6603, Cosentyx Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Proceeds From Chagas Treatment Priority Review Voucher Will Help Ensure Access
US FDA approved its first treatment for the tropical disease and awarded a priority review voucher that will be sold as per agreement between development partners.
DNDi Adds Affordable Ravidasvir Combo To Asian HCV Trials
DNDi is progressing its five-year initiative to improve access to affordable combination therapies for hepatitis C through new agreements for ravidasvir, which will be tested in trials in Malaysia and Thailand.
Company Information
- Industry
- Academic and Research Institutions
- Other Names / Subsidiaries
-
- Global Antibiotic Research and Development Partnership (GARDP)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice